Gram Research analysis shows that the FINE Index, a new prediction tool combining age, nutrition, cancer stage, physical frailty, and hormone therapy, predicted breast cancer survival in older adults with 73 to 77 percent accuracy, outperforming standard cancer staging alone. Tested on 2,166 patients across two hospitals, the tool successfully predicted 3, 5, and 10-year survival rates and could help doctors make more personalized treatment decisions for elderly breast cancer patients.
Researchers created a new prediction tool called the FINE Index to help doctors better estimate how long older breast cancer patients will survive after surgery. The tool combines information about a patient’s age, nutrition level, cancer stage, physical weakness, and treatment type. In tests with over 2,100 patients, the FINE Index was more accurate than current methods at predicting 3, 5, and 10-year survival rates. This personalized approach could help doctors make better treatment decisions for elderly patients with breast cancer.
Key Statistics
A 2026 retrospective study of 2,166 elderly breast cancer patients found that the FINE Index achieved 76.7 percent accuracy in predicting survival in the training cohort, 73.9 percent in internal validation, and 73.1 percent in external validation across different hospitals.
According to research reviewed by Gram, the FINE Index predicted 3-year, 5-year, and 10-year overall survival with accuracy scores exceeding 70 percent, demonstrating consistent performance across multiple time points in 2,166 elderly breast cancer patients.
A 2026 study of 2,166 older breast cancer patients found that the FINE Index, which combines five factors including age, nutrition, cancer stage, frailty, and hormone therapy, provided better survival predictions and greater clinical utility than TNM cancer staging alone.
Research on 2,166 elderly breast cancer patients showed that among high-risk patients identified by the FINE Index, those receiving chemotherapy appeared to have improved overall survival, though this finding requires confirmation in future prospective studies.
The Quick Take
- What they studied: Can a new prediction tool combining frailty, nutrition, and cancer stage better forecast survival in older breast cancer patients than existing methods?
- Who participated: 2,166 older adults with breast cancer from two hospitals in China. The main group had 1,132 patients, with 489 used to test the tool internally and 545 from another hospital used for final testing.
- Key finding: The FINE Index predicted survival with 73 to 77 percent accuracy across all patient groups, outperforming standard cancer staging systems that doctors currently use.
- What it means for you: If you or a loved one is an older adult facing breast cancer surgery, this tool could help your doctor give you more personalized predictions about your likely outcome and better treatment recommendations. However, this is a research finding that needs to be tested in more hospitals before becoming standard practice.
The Research Details
Researchers looked back at medical records from 2,166 older breast cancer patients treated at two hospitals in China. They divided the patients into three groups: a main training group of 1,132 patients used to develop the prediction tool, an internal validation group of 489 patients used to test it at the same hospital, and an external validation group of 545 patients from a different hospital used for final testing. This approach helps ensure the tool works reliably across different patient populations and settings.
To build the FINE Index, researchers identified which patient characteristics were most important for predicting survival. They used statistical methods to narrow down hundreds of possible factors to just five key predictors: patient age, nutritional status (measured by a score called the prognostic nutritional index), cancer stage (TNM staging), physical frailty (measured by a five-item frailty scale), and whether patients received hormone therapy. These five factors were combined into a single scoring system.
The researchers then tested how well the FINE Index predicted whether patients would survive 3, 5, and 10 years after surgery. They compared its accuracy to the standard TNM cancer staging system that doctors typically use alone.
Older adults with breast cancer often have worse outcomes than younger patients, partly because they may have other health problems, poor nutrition, or physical weakness that doctors don’t always account for. A tool that measures these additional factors alongside cancer stage could help doctors identify which patients are at highest risk and need more aggressive treatment, and which patients might do well with gentler approaches. This personalized approach could improve treatment decisions and help set realistic expectations for patients and families.
This study has several strengths: it included over 2,100 patients, used rigorous statistical methods to identify important factors, and tested the tool in multiple patient groups including patients from a different hospital. However, because it looked backward at existing medical records rather than following patients forward, doctors cannot be completely certain about cause and effect. The study was also conducted in China, so the results may need testing in other countries and populations before becoming standard practice worldwide.
What the Results Show
The FINE Index successfully predicted survival in all three patient groups tested. In the main training group, the tool was 76.7 percent accurate at predicting outcomes. When tested on new patients at the same hospital, accuracy was 73.9 percent. When tested on patients from a completely different hospital, accuracy remained strong at 73.1 percent. This consistency across different groups suggests the tool is reliable and not just lucky with one specific set of patients.
The tool was particularly good at predicting survival at important time points. For patients followed for 3 years, 5 years, and 10 years after surgery, the FINE Index achieved accuracy scores above 70 percent at each time point. This means doctors could use it to give patients realistic information about their chances of surviving these important milestones.
When compared to the standard TNM cancer staging system that doctors currently use, the FINE Index provided better predictions and more useful information for clinical decision-making. The tool also helped identify which patients were at highest risk and might benefit most from additional treatments like chemotherapy. Researchers found that among high-risk patients identified by the FINE Index, those who received chemotherapy appeared to have better survival, though this finding needs confirmation in future studies.
The five factors included in the FINE Index each contributed important information. Age mattered because older patients generally have more health challenges. Nutritional status was important because poor nutrition weakens the immune system and slows recovery. Cancer stage remained crucial, as more advanced cancers are harder to treat. Physical frailty was significant because weak patients tolerate treatments poorly. Hormone therapy status mattered because some breast cancers respond well to this treatment. Together, these five factors painted a much more complete picture of each patient’s situation than cancer stage alone.
Previous research has shown that older breast cancer patients have worse outcomes, but doctors haven’t had good tools to predict individual survival or decide on personalized treatment. This study builds on earlier work showing that frailty and nutrition matter in cancer patients by combining these factors with standard cancer information into one practical tool. The FINE Index represents an advance because it integrates multiple dimensions of patient health rather than focusing only on the cancer itself.
This study looked backward at medical records, which means researchers couldn’t control all the factors that might affect results. The study was conducted in China, so results may differ in other countries with different populations and healthcare systems. The finding about chemotherapy helping high-risk patients is based on observation rather than a controlled experiment, so it should be considered a suggestion for future research rather than proof. The tool needs to be tested in more hospitals and countries before doctors can confidently use it everywhere. Additionally, the study didn’t examine whether using this tool actually changed treatment decisions or improved patient outcomes in real practice.
The Bottom Line
For older adults with breast cancer, discuss the FINE Index with your doctor to get a more personalized prediction of your likely survival and treatment options. The tool appears reliable based on testing in over 2,100 patients, but it should be used alongside your doctor’s clinical judgment and your personal preferences, not as a replacement for them. High-risk patients identified by the tool may benefit from discussing chemotherapy options with their oncologist. These recommendations have moderate confidence because the tool is new and needs testing in more settings.
This research matters most for older adults diagnosed with breast cancer, their families, and their doctors. It may be particularly helpful for patients and doctors trying to decide whether aggressive treatments are appropriate. Younger breast cancer patients and those with other cancer types should not assume these findings apply to them. Healthcare systems and hospitals should consider testing whether adopting this tool improves treatment decisions and outcomes.
The FINE Index provides predictions about 3, 5, and 10-year survival, so these are the key timeframes to discuss with your doctor. Benefits from improved treatment decisions based on this tool would likely appear over months to years as treatment plans are adjusted. However, this is a new tool, so widespread adoption and real-world benefits may take several years.
Frequently Asked Questions
What is the FINE Index and how does it help predict breast cancer survival in older adults?
The FINE Index is a prediction tool combining five factors: age, nutritional status, cancer stage, physical frailty, and hormone therapy. In a 2,166-patient study, it predicted survival with 73 to 77 percent accuracy, better than standard cancer staging alone, helping doctors give older patients more personalized survival estimates.
How accurate is the FINE Index at predicting long-term survival?
The FINE Index achieved over 70 percent accuracy at predicting 3-year, 5-year, and 10-year survival rates across 2,166 patients tested at multiple hospitals. This consistency suggests it reliably forecasts outcomes at important time milestones for older breast cancer patients.
Can the FINE Index help doctors decide whether older patients should receive chemotherapy?
The study suggests that high-risk patients identified by the FINE Index may benefit from chemotherapy, as those who received it showed improved survival. However, this finding is preliminary and needs confirmation. Your doctor should use the FINE Index alongside other factors when discussing treatment options.
Is the FINE Index ready to use in all hospitals and countries?
The FINE Index was developed and tested in Chinese hospitals with 2,166 patients. While results are promising, the tool needs testing in more hospitals and different populations before becoming standard practice worldwide. Ask your doctor whether they use or have access to this tool.
What factors does the FINE Index measure and why do they matter for breast cancer survival?
The FINE Index measures age, nutrition, cancer stage, physical frailty, and hormone therapy. These factors matter because older patients with poor nutrition and weakness tolerate treatment poorly, while cancer stage and hormone therapy directly affect treatment options and response. Together, they provide a complete picture of each patient’s situation.
Want to Apply This Research?
- Track your nutritional intake weekly by logging protein, calories, and key nutrients, since the prognostic nutritional index is a core component of the FINE Index. Monitor your physical activity and strength with simple measures like walking distance or ability to climb stairs.
- Work with your healthcare team to optimize nutrition through adequate protein intake and calorie consumption, which directly impacts the nutritional component of the FINE Index. Engage in gentle physical activity as tolerated to maintain strength and reduce frailty scores.
- Record monthly assessments of physical function, nutritional status, and any changes in treatment or symptoms. Share these records with your oncology team to help them track whether interventions are improving your predicted outcomes over time.
This research describes a new prediction tool for breast cancer survival in older adults. The FINE Index is a research finding that has not yet been widely adopted in clinical practice. Do not use this information to make treatment decisions without consulting your oncologist or healthcare provider. The study was conducted in China and results may vary in other populations. This tool should complement, not replace, your doctor’s clinical judgment and recommendations. If you have breast cancer or suspect you might, speak with a qualified healthcare professional about your individual situation, prognosis, and treatment options.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.